Personalized Cancer Therapy Found Valuable

BOSTON -- U.S. medical scientists said they've conducted a trial that supports first-line use of targeted therapy to treat lung cancer. The Massachusetts General Hospital Cancer Center researchers said the study -- the first such U.S. clinical genetic screening trial -- supports the use of targeted therapies as primary treatments, rather than only after standard chemotherapy has failed. Investigators found gefitinib (Iressa) treatment considerably improved the outcomes for non-small-cell-lung-cancer, although additional research is required before such a strategy can be used for routine treatment. "This is a pivotal clinical trial that demonstrates the power of personalized medicine in lung cancer treatment," said D...